Nadalin, Silvio

Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial

Geissler, E. K., Schnitzbauer, A. A., Zülke, C., Lamby, P. E., Proneth, A., Duvoux, C., Burra, P., Jauch, K.-W., Rentsch, M., Ganten, T. M., et al. (2016) · Transplantation

Hepatocellular Carcinoma Treatment and PrognosisOrgan Transplantation Techniques and Outcomes

Cited by 433

Transforming Growth Factor-β (TGF-β)-mediated Connective Tissue Growth Factor (CTGF) Expression in Hepatic Stellate Cells Requires Stat3 Signaling Activation

Liu, Y., Liu, H., Meyer, C., Li, J., Nadalin, S., Königsrainer, A., Weng, H., Dooley, S., & ten Dijke, P. (2013) · Journal of Biological Chemistry

Liver physiology and pathologyTGF-β signaling in diseases

Cited by 181

Metabolic crosstalk between fatty pancreas and fatty liver: effects on local inflammation and insulin secretion

Gerst, F., Wagner, R., Kaiser, G., Panse, M., Heni, M., Machann, J., Bongers, M. N., Sartorius, T., Sipos, B., Fend, F., et al. (2017) · Diabetologia

Pancreatic function and diabetesAdipokines, Inflammation, and Metabolic Diseases

Cited by 151

Volumetric and functional recovery of the liver after right hepatectomy for living donation

Nadalin, S., Testa, G., Malagó, M., Beste, M., Frilling, A., Schroeder, T., Jochum, C., Gerken, G., & Broelsch, C. E. (2004) · Liver Transplantation

Organ Transplantation Techniques and OutcomesLiver physiology and pathology

Cited by 130

International liver transplantation consensus statement on end-stage liver disease due to nonalcoholic steatohepatitis and liver transplantation

Tsochatzis, E., Coilly, A., Nadalin, S., Levistky, J., Tokat, Y., Ghobrial, M., Klinck, J., & Berenguer, M. (2019) · Transplantation

Organ Transplantation Techniques and OutcomesLiver Disease Diagnosis and Treatment

Cited by 105

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus

Mahling, M., Schork, A., Nadalin, S., Fritsche, A., Heyne, N., & Guthoff, M. (2019) · Kidney and Blood Pressure Research

Diabetes Treatment and ManagementRenal Transplantation Outcomes and Treatments

Cited by 95

Towards improved hepatocyte cultures: Progress and limitations

Ruoß, M., Vosough, M., Königsrainer, A., Nadalin, S., Wagner, S., Sajadian, S., Huber, D., Heydari, Z., Ehnert, S., Hengstler, J. G., et al. (2020) · Food and Chemical Toxicology

Drug-Induced Hepatotoxicity and ProtectionAnimal testing and alternatives

Cited by 77

Recurrence of primary sclerosing cholangitis after liver transplantation - analysing the European Liver Transplant Registry and beyond

Visseren, T., Erler, N. S., Polak, W. G., Adam, R., Karam, V., Vondran, F. W. R., Ericzon, B., Thorburn, D., IJzermans, J. N. M., Paul, A., et al. (2021) · Transplant International

Liver Diseases and ImmunityOrgan Transplantation Techniques and Outcomes

Cited by 70

Low-dose alemtuzumab induction in a tailored immunosuppression protocol for sensitized kidney transplant recipients

Guthoff, M., Berger, K., Althaus, K., Mühlbacher, T., Bakchoul, T., Steurer, W., Nadalin, S., Königsrainer, A., & Heyne, N. (2020) · BMC Nephrology

Renal Transplantation Outcomes and TreatmentsTransplantation: Methods and Outcomes

Cited by 23